Evidence map›Paper›PMID 34091830›Full record

ArticleBreast cancer research and treatment2021

Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.

Jean Zheng Boyer, Gail D Lewis Phillips, Hiro Nitta, Karl Garsha, Brittany Admire, Robert Kraft, Eslie Dennis, Elizabeth Vela, Penny Towne

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla.International journal of molecular sciences · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jean Zheng BoyerRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA. jean.boyer@roche.com.ORCID http://orcid.org/0000-0002-5518-5706
Gail D Lewis PhillipsGenentech, Inc., South San Francisco, CA, USA.
Hiro NittaRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Karl GarshaRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Brittany AdmireRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Robert KraftRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Eslie DennisRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Elizabeth VelaRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Penny TowneRoche Tissue Diagnostics, 1910 E Innovation Park Drive, Tucson, AZ, 85755, USA.
Roche (United States) · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell spheroids and aggregates generated from three-dimensional (3D) cell culture methods are similar to in vivo tumors in terms of tissue morphology, biology, and gene expression, unlike cells grown in 2D cell cultures. Breast cancer heterogeneity is one of the main drug resistant mechanisms and needs to be overcome in order to increase the efficacy of drug activity in its treatments.

methodsWe performed a unique 3D cell culture and drug efficacy study with trastuzumab emtansine (Kadcyla®, T-DM1) across five breast cancer cell lines (BT-474, SK-BR-3, MDA-MB-361, MDA-MB-175, and MCF-7) that were previously investigated in 2D cell culture. We performed HER2 IHC staining, cell viability experiments, Gene-protein-assay (GPA), and T-DM1 internalization studies.

resultsWe obtained significantly different results including higher IC

conclusionOur study demonstrated that the difference of T-DM1 drug activity in 3D spheroids or aggregates might be due to tumor heterogeneity and less efficient internalization of T-DM1 that is not seen using 2D cell culture models. Drug studies using 3D cell culture are expected to provide biologically relevant models for determining drug activity in tumor tissue in future drug response and resistance research.

Indexed as

Breast NeoplasmsMaytansineAdo-Trastuzumab EmtansineCell Culture TechniquesCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansTrastuzumabAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine KinasesMaytansineTrastuzumab3D cell cultureBreast cancer cell linesDrug efficacy studyDrug resistanceHeterogeneityT-DM1

Identifiers

PMID34091830
PMCPMC8233276
OpenAlexW3172143512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.